You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameBetamethasone
Accession NumberDB00443  (APRD00513)
TypeSmall Molecule
GroupsApproved, Vet Approved
Description

A glucocorticoid given orally, parenterally, by local injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated. Its lack of mineralocorticoid properties makes betamethasone particularly suitable for treating cerebral edema and congenital adrenal hyperplasia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p724)

Structure
Thumb
Synonyms
16beta-Methyl-1,4-pregnadiene-9alpha-fluoro-11beta,17alpha,21-triol-3,20-dione
16β-Methyl-1,4-pregnadiene-9α-fluoro-11β,17α,21-triol-3,20-dione
9-Fluoro-16beta-methylprednisolone
9-Fluoro-16β-methylprednisolone
9alpha-Fluoro-16beta-methylprednisolone
9α-Fluoro-16β-methylprednisolone
beta-Methasone alcohol
Betadexamethasone
Betametasona
Betamethasone
Betamethasonum
Betamethasonvalerat Mikron
Rinderon
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Beben Gel 0.025%gel0.025 %topicalParke Davis Division, Warner Lambert Canada Inc.1973-12-311999-04-08Canada
Betacort Scalp Lotion 0.1%liquid.1 %topicalIcn Canada Ltd.1981-12-312005-04-26Canada
Betaderm Crm 0.05%cream0.05 %topicalTaro Pharmaceuticals Inc1979-12-31Not applicableCanada
Betaderm Crm 0.1%cream.1 %topicalTaro Pharmaceuticals Inc1979-12-31Not applicableCanada
Betaderm Lotion 0.1%lotion1.22 mgtopicalTaro Pharmaceuticals Inc1979-12-31Not applicableCanada
Betaderm Ont 0.05%ointment0.5 mgtopicalTaro Pharmaceuticals Inc1979-12-31Not applicableCanada
Betaderm Ont 0.1%ointment1 mgtopicalTaro Pharmaceuticals Inc1988-12-31Not applicableCanada
Betagel - 0.1%gel.1 %topicalUcb Inc1996-12-061998-04-21Canada
Betamethasone Dipropionatecream.5 mg/gtopicalA S Medication Solutions Llc1984-06-26Not applicableUs
Betamethasone Dipropionatecream.5 mg/gtopicalE. Fougera & Co. a division of Fougera Pharmaceuticals Inc.1984-06-26Not applicableUs
Betamethasone Dipropionateointment.5 mg/gtopicalA S Medication Solutions Llc1984-09-04Not applicableUs
Betamethasone Dipropionatecream.5 mg/gtopicalA S Medication Solutions Llc1984-06-26Not applicableUs
Betamethasone Dipropionateointment.5 mg/gtopicalPrasco Laboratories2012-05-15Not applicableUs
Betamethasone Dipropionateointment.5 mg/gtopicalE. Fougera & Co. a division of Fougera Pharmaceuticals Inc.1984-09-04Not applicableUs
Betamethasone Valeratecream1 mg/gtopicalA S Medication Solutions Llc1983-08-31Not applicableUs
Betamethasone Valeratelotion1 mg/mLtopicalE. Fougera & Co. a division of Fougera Pharmaceuticals Inc.1983-08-31Not applicableUs
Betamethasone Valeratecream1 mg/gtopicalE. Fougera & Co. a division of Fougera Pharmaceuticals Inc.1983-08-31Not applicableUs
Betamethasone Valeratecream1 mg/gtopicalREMEDYREPACK INC.2013-06-10Not applicableUs
Betamethasone Valerateointment1 mg/gtopicalE. Fougera & Co. a division of Fougera Pharmaceuticals Inc.1983-08-31Not applicableUs
Betamethasone Valeratecream1 mg/gtopicalLake Erie Medical DBA Quality Care Products LLC1983-08-31Not applicableUs
Betamethasone Valeratelotion1 mg/mLtopicalA S Medication Solutions Llc1983-08-31Not applicableUs
Betamethasone Valerate Lot 0.1% USPlotion1.22 mgtopicalPharmaco Canada Inc.1987-12-312001-07-19Canada
Betaprolene Cream 0.05%cream.05 %topicalNeolab Inc1994-12-311997-08-12Canada
Betaprolene Ointment 0.05%ointment.05 %topicalNeolab Inc1994-12-311997-08-12Canada
Betaprone Cream 0.05%cream.64 mgtopicalNeolab Inc1995-12-311998-08-13Canada
Betaprone Lotion 0.05%lotion.64 mgtopicalNeolab Inc1994-12-311998-08-13Canada
Betaprone Ointment 0.05%ointment.64 mgtopicalNeolab Inc1995-12-311998-08-13Canada
Beteflampatch2.25 mgtopicalCipher Pharmaceuticals Inc2016-04-05Not applicableCanada
Betnesol Eye and Ear Dropsdrops.1 %ophthalmic; oticGlaxo Canada Inc1963-12-311998-07-30Canada
Betnesol Eye and Ear Drops 0.1%liquid0.1 %ophthalmic; oticShire Pharma Canada Ulc1997-04-012002-10-18Canada
Betnesol Pellets 0.1mgtablet0.1 mgtopicalGlaxo Canada Inc1964-12-311998-07-30Canada
Betnesol Retention Enema 5mg/100mlenema5 mgrectalPaladin Labs Inc1997-04-01Not applicableCanada
Betnesol Retention Enemasenema5 mgrectalGlaxo Canada Inc1964-12-311998-07-30Canada
Betnesol Tab 0.5mgtablet.5 mgoralGlaxo Canada Inc1963-12-311996-09-10Canada
Betnesol Tabletstablet (effervescent)0.5 mgoralShire Pharma Canada Ulc1995-12-312001-08-02Canada
Betnovate 1/2 Crm 0.05%cream.05 %topicalGlaxo Canada Inc1965-12-311998-07-30Canada
Betnovate 1/2 Lot 0.05%lotion.05 %topicalGlaxo Canada Inc1965-12-311998-07-30Canada
Betnovate 1/2 Ont 0.05%ointment.05 %topicalGlaxo Canada Inc1965-12-311998-07-30Canada
Betnovate Crm 0.1%cream.1 %topicalGlaxo Canada Inc1965-12-311998-07-30Canada
Betnovate Lot 0.1%lotion.1 %topicalGlaxo Canada Inc1965-12-311998-07-30Canada
Betnovate Lotion 0.1%lotion0.1 %topicalShire Pharma Canada Ulc1998-01-212002-04-29Canada
Betnovate Ont 0.1%ointment.1 %topicalGlaxo Canada Inc1965-12-311998-07-30Canada
Celestoderm Vointment0.1 %topicalValeant Canada Lp Valeant Canada S.E.C.2011-10-19Not applicableCanada
Celestoderm Vcream0.1 %topicalValeant Canada Lp Valeant Canada S.E.C.2011-10-19Not applicableCanada
Celestoderm V Crm 0.1%cream0.1 %topicalSchering Plough Canada Inc1965-12-312005-08-05Canada
Celestoderm V Ont 0.1%ointment0.1 %topicalSchering Plough Canada Inc1965-12-312005-08-05Canada
Celestoderm V/2ointment0.05 %topicalValeant Canada Lp Valeant Canada S.E.C.2011-10-19Not applicableCanada
Celestoderm V/2cream0.05 %topicalValeant Canada Lp Valeant Canada S.E.C.2011-10-19Not applicableCanada
Celestoderm V/2 Cream .05%cream0.05 %topicalSchering Plough Canada Inc1965-12-312005-08-05Canada
Celestoderm V/2 Ointment 0.05%ointment0.05 %topicalSchering Plough Canada Inc1965-12-312005-08-05Canada
Celestone Repetabs 1mgtablet (extended-release)1 mgoralSchering Plough Canada Inc1983-12-311999-07-22Canada
Celestone Tab 0.5mgtablet0.5 mgoralSchering Plough Canada Inc1961-12-311998-11-17Canada
Diprolenecream0.5 mgtopicalMerck Canada Inc1987-12-31Not applicableCanada
Diproleneointment0.5 mgtopicalMerck Canada Inc1985-12-31Not applicableCanada
Diprolenelotion0.5 mgtopicalMerck Canada Inc1989-12-31Not applicableCanada
Diprolenelotion.5 mg/mLtopicalMerck Sharp & Dohme Corp.1988-08-01Not applicableUs
Diproleneointment.5 mg/gtopicalMerck Sharp & Dohme Corp.1983-07-27Not applicableUs
Diprolene AFcream.5 mg/gtopicalMerck Sharp & Dohme Corp.1987-04-27Not applicableUs
Diprosone Cream 0.05%cream0.05 %topicalMerck Canada Inc1975-12-31Not applicableCanada
Diprosone Lotion 0.05%lotion0.05 %topicalMerck Canada Inc1977-12-31Not applicableCanada
Diprosone Ointment 0.05%ointment0.05 %topicalMerck Canada Inc1976-12-31Not applicableCanada
Luxiqaerosol, foam0.12 %topicalGlaxosmithkline Inc2012-02-10Not applicableCanada
Luxiqaerosol, foam1.2 mg/gtopicalPrestium Pharma, Inc.2009-10-16Not applicableUs
Luxiqaerosol, foam1.2 mg/gtopicalPhysicians Total Care, Inc.2005-09-21Not applicableUs
Occlucort Film Forming Lot 0.05lotion.05 %topicalGenderm Corporation1990-12-311998-08-06Canada
Prevex B Cream 0.1%cream.1 %topicalGlaxosmithkline Inc1989-12-31Not applicableCanada
Pro-lene Glycol Cream - 0.05%cream0.05 %topicalPro Doc Limitee1997-02-272002-08-02Canada
Pro-lene Glycol Lotion - 0.05%lotion0.05 %topicalPro Doc Limitee1997-02-272002-08-02Canada
Pro-lene Glycol Ointment - 0.05%ointment0.05 %topicalPro Doc Limitee1997-02-272002-08-02Canada
Pro-sone Cream - 0.05%cream0.05 %topicalPro Doc Limitee1997-02-272002-08-02Canada
Pro-sone Lotion - 0.05%lotion.05 %topicalPro Doc Limitee1997-02-272002-08-02Canada
Pro-sone Ointment - 0.05%ointment.05 %topicalPro Doc Limitee1997-02-272002-08-02Canada
Ratio-ectosonelotion0.1 %topicalTeva Canada Limited1986-12-31Not applicableCanada
Ratio-ectosone Mild Cream 0.05%cream0.05 %topicalTeva Canada Limited1981-12-31Not applicableCanada
Ratio-ectosone Mild Lotion 0.05%lotion0.05 %topicalTeva Canada Limited1986-12-31Not applicableCanada
Ratio-ectosone Regular Cream 0.1%cream0.1 %topicalTeva Canada Limited1981-12-31Not applicableCanada
Ratio-ectosone Regular Lotion 0.1%lotion0.1 %topicalTeva Canada Limited1987-12-31Not applicableCanada
Ratio-topilenecream0.5 mgtopicalTeva Canada Limited1990-12-31Not applicableCanada
Ratio-topileneointment0.5 mgtopicalTeva Canada Limited1990-12-31Not applicableCanada
Ratio-topilenelotion0.5 mgtopicalTeva Canada Limited1993-12-31Not applicableCanada
Ratio-topisonelotion0.05 %topicalTeva Canada Limited1990-12-31Not applicableCanada
Ratio-topisonecream.05 %topicalTeva Canada Limited1993-12-31Not applicableCanada
Ratio-topisoneointment0.05 %topicalTeva Canada Limited1990-12-31Not applicableCanada
Rhoprolene Glycol Cream 0.5mg/gmcream0.5 mgtopicalRhodiapharm Inc1992-12-311996-09-09Canada
Rhoprolene Glycol Lotion 0.5mg/gmlotion.5 mgtopicalRhodiapharm Inc1992-12-311996-09-09Canada
Rhoprolene Glycol Ointment 0.5mg/gmointment.5 mgtopicalRhodiapharm Inc1992-12-311996-09-09Canada
Rhoprosone Cream 0.05%cream.5 mgtopicalRhodiapharm Inc1992-12-311996-09-09Canada
Rhoprosone Lotion 0.05%lotion.05 %topicalRhodiapharm Inc1992-12-311996-09-09Canada
Rhoprosone Oint 0.05%ointment.05 %topicalRhodiapharm Inc1992-12-311996-09-09Canada
Rivasone Scalp Lot 0.1%lotion.1 %topicalLaboratoire Riva Inc1993-12-31Not applicableCanada
Rolene Cream 0.05%cream.05 %topicalLaboratoire Riva Inc1995-12-31Not applicableCanada
Rolene Lotion 0.05%lotion.05 %topicalLaboratoire Riva Inc1995-12-31Not applicableCanada
Rolene Ointment 0.05%ointment.05 %topicalLaboratoire Riva Inc1995-12-31Not applicableCanada
Rosone Cream 0.05%cream.05 %topicalLaboratoire Riva Inc1995-12-31Not applicableCanada
Rosone Lotion 0.05%lotion.05 %topicalLaboratoire Riva Inc1995-12-31Not applicableCanada
Rosone Ointment 0.05%ointment.05 %topicalLaboratoire Riva Inc1995-12-31Not applicableCanada
Sernivospray.5 mg/gtopicalPromius Pharma, LLC2016-02-22Not applicableUs
Taro Sone Lot 0.05%lotion.05 %topicalTaro Pharmaceuticals Inc1992-12-31Not applicableCanada
Taro Sone Ontointment.05 %topicalTaro Pharmaceuticals Inc1992-12-312001-08-21Canada
Taro-sone Cream 0.05%cream.5 mgtopicalTaro Pharmaceuticals Inc1992-12-31Not applicableCanada
Valisone Scalp Lotionlotion0.1 %topicalValeant Canada Lp Valeant Canada S.E.C.1980-11-04Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Betamethasonecream.5 mg/gtopicalImpax Generics2004-01-23Not applicableUs
Betamethasone Dipropionatecream.64 mg/gtopicalRebel Distributors Corp.1984-02-26Not applicableUs
Betamethasone Dipropionatecream.5 mg/gtopicalProficient Rx LP2008-09-23Not applicableUs
Betamethasone Dipropionatecream.5 mg/gtopicalH.J. Harkins Company, Inc.1984-02-26Not applicableUs
Betamethasone Dipropionatelotion.5 mg/mLtopicalE. Fougera & Co. a division of Fougera Pharmaceuticals Inc.1985-08-12Not applicableUs
Betamethasone Dipropionatecream, augmented.5 mg/gtopicalProficient Rx LP2003-12-09Not applicableUs
Betamethasone Dipropionatecream.5 mg/gtopicalH.J. Harkins Company, Inc.2008-09-23Not applicableUs
Betamethasone Dipropionateointment.5 mg/gtopicalPhysicians Total Care, Inc.1994-04-27Not applicableUs
Betamethasone Dipropionatecream.5 mg/gtopicalLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-03-26Not applicableUs
Betamethasone Dipropionatecream.64 mg/gtopicalSTAT Rx USA LLC1984-02-26Not applicableUs
Betamethasone Dipropionatelotion, augmented.5 mg/mLtopicalTaro Pharmaceuticals U.S.A., Inc.2007-05-21Not applicableUs
Betamethasone Dipropionateointment, augmented.5 mg/gtopicalE. Fougera & CO., A division of Fougera Pharmaceuticals Inc.1999-06-22Not applicableUs
Betamethasone Dipropionatecream.5 mg/gtopicalPerrigo New York Inc2006-09-28Not applicableUs
Betamethasone Dipropionateointment, augmented.5 mg/gtopicalTaro Pharmaceuticals U.S.A., Inc.2004-10-12Not applicableUs
Betamethasone Dipropionatelotion, augmented.5 mg/mLtopicalE. Fougera & Co. a division of Fougera Pharmaceuticals Inc.2007-05-21Not applicableUs
Betamethasone Dipropionatecream.5 mg/gtopicalPhysicians Total Care, Inc.1994-12-15Not applicableUs
Betamethasone Dipropionatecream.5 mg/gtopicalPreferred Pharmaceuticals, Inc2012-04-23Not applicableUs
Betamethasone Dipropionateointment, augmented.5 mg/gtopicalActavis Mid Atlantic LLC2007-01-03Not applicableUs
Betamethasone Dipropionatecream.5 mg/gtopicalPhysicians Total Care, Inc.2011-09-06Not applicableUs
Betamethasone Dipropionatecream, augmented.5 mg/gtopicalTaro Pharmaceuticals U.S.A., Inc.2003-12-09Not applicableUs
Betamethasone Dipropionategel.5 mg/gtopicalE. Fougera & Co. a division of Fougera Pharmaceuticals Inc.2003-05-13Not applicableUs
Betamethasone Dipropionatecream.5 mg/gtopicalPreferred Pharmaceuticals, Inc.2014-09-19Not applicableUs
Betamethasone Dipropionatelotion.5 mg/gtopicalPerrigo New York Inc2006-06-30Not applicableUs
Betamethasone Dipropionategel.5 mg/gtopicalTaro Pharmaceuticals U.S.A., Inc.2003-12-02Not applicableUs
Betamethasone Dipropionateointment.5 mg/gtopicalActavis Mid Atlantic LLC2002-08-26Not applicableUs
Betamethasone Dipropionatecream.5 mg/gtopicalGlenmark Pharmaceuticals Inc., Usa2008-09-23Not applicableUs
Betamethasone Dipropionatecream, augmented.5 mg/gtopicalE. Fougera & Co. a division of Fougera Pharmaceuticals Inc.2003-12-09Not applicableUs
Betamethasone Dipropionatelotion.5 mg/gtopicalA S Medication Solutions Llc2006-06-30Not applicableUs
Betamethasone Dipropionateointment.5 mg/gtopicalPreferred Pharmaceuticals, Inc1987-02-03Not applicableUs
Betamethasone Dipropionateointment.05 mg/gtopicalRebel Distributors Corp.1987-02-03Not applicableUs
Betamethasone Dipropionatecream.64 mg/gtopicalTaro Pharmaceuticals U.S.A., Inc.1992-04-30Not applicableUs
Betamethasone Dipropionatecream.5 mg/gtopicalActavis Mid Atlantic LLC2002-09-03Not applicableUs
Betamethasone Dipropionategel.64 mg/gtopicalPhysicians Total Care, Inc.2006-10-17Not applicableUs
Betamethasone Dipropionate Augmentedlotion.64 mg/mLtopicalPhysicians Total Care, Inc.2011-07-27Not applicableUs
Betamethasone Valerateointment1 mg/gtopicalRebel Distributors Corp2009-10-23Not applicableUs
Betamethasone Valeratecream1 mg/gtopicalA S Medication Solutions Llc1988-01-06Not applicableUs
Betamethasone Valeratecream1.2 mg/gtopicalPreferred Pharmaceuticals, Inc.2014-11-26Not applicableUs
Betamethasone Valeratecream1 mg/gtopicalTaro Pharmaceuticals U.S.A., Inc.1988-01-06Not applicableUs
Betamethasone Valerateointment1.2 mg/gtopicalActavis Mid Atlantic LLC2002-09-01Not applicableUs
Betamethasone Valeratelotion1 mg/mLtopicalPhysicians Total Care, Inc.2004-11-09Not applicableUs
Betamethasone Valeratecream1.2 mg/gtopicalProficient Rx LP2002-09-01Not applicableUs
Betamethasone Valeratecream1 mg/gtopicalSTAT Rx USA LLC2009-10-23Not applicableUs
Betamethasone Valeratecream1.2 mg/gtopicalActavis Mid Atlantic LLC2002-09-01Not applicableUs
Betamethasone Valeratecream1.2 mg/gtopicalG&W Laboratories, Inc.2016-03-31Not applicableUs
Betamethasone Valerateointment1.2 mg/gtopicalProficient Rx LP2002-09-01Not applicableUs
Betamethasone Valerateointment1 mg/gtopicalPhysicians Total Care, Inc.1997-05-02Not applicableUs
Betamethasone Valerateointment1.2 mg/gtopicalG&W Laboratories, Inc.2015-10-16Not applicableUs
Betamethasone Valeratelotion1 mg/mLcutaneousSTI Pharma1985-07-31Not applicableUs
Betamethasone Valerateaerosol, foam1.2 mg/gtopicalPerrigo New York Inc2013-01-15Not applicableUs
Betamethasone Valeratecream1 mg/gtopicalPhysicians Total Care, Inc.1995-10-16Not applicableUs
Betamethasone Valerateointment1.2 mg/gtopicalA S Medication Solutions Llc2002-09-01Not applicableUs
Betamethasone Valeratecream1 mg/gtopicalRebel Distributors Corp.1985-05-14Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Betamethasone Sp 24mg/2ml PFinjection, solution12 mg/mLepidural; intramuscular; intraspinal; intrathecalUs Compounding, Inc2013-12-202015-12-29Us
Dr. Throwers Betacream.05 g/100gtopicalDr. Thrower's Skincare, Inc.2015-05-15Not applicableUs
Dr. Throwers Betaointment.05 g/100gtopicalDr. Thrower's Skincare, Inc.2015-05-15Not applicableUs
International Brands
NameCompany
BentelanDefiante
BetnovateGlaxoSmithKline
CelestamineSchering-Plough
CelestoneSchering-Plough
DiprosoneSchering-Plough
FucibetLEO
ProcortNot Available
RinderonShionogi Seiyaku
Brand mixtures
NameLabellerIngredients
Beta 1 KitOaklock, Llc
BetajectSandoz Canada Incorporated
Betamethasone ClotrimazoleStat Rx USA
Betamethasone Combo 6mg/ml PFUs Compounding, Inc
Betamethasone Combo 7mg/mlUs Compounding, Inc
Betamethasone Sodium Phosphate and Betamethasone AcetateAmerican Regent, Inc.
Betamycin Ophthalmic/otic SolutionSterimax Inc
Calcipotriene 0.005% and Betamethasone Dipropionate 0.064%Sandoz Inc.
Calcipotriene and Betamethasone DipropionatePerrigo New York Inc
Celestone SoluspanMerck Sharp & Dohme Corp.
Clotrimazole and Betamethasone DipropionateE. Fougera & Co. a division of Fougera Pharmaceuticals Inc.
Diprogen OintmentMerck Canada Inc
DiprosalicMerck Canada Inc
Dom-gentamicin-betamethasoneDominion Pharmacal
Dovobet GelLeo Pharma Inc
Dovobet OintmentLeo Pharma Inc
Dr. Throwers Pbc No. 1Dr. Thrower's Skincare, Inc.
EnstilarLEO Pharma Inc.
Garasone Ophthalmic and Otic SolutionMerck Canada Inc
Garasone Ophthalmic OintmentMerck Canada Inc
Lotriderm CreamMerck Canada Inc
LotrisoneMerck Sharp & Dohme Corp.
Marbeta 25 KitAsclemed Usa, Inc.
PMS-clotrimazole-betamethasonePharmascience Inc
PMS-gentamicin-betamethasonePharmascience Inc
Ratio-topisalicTeva Canada Limited
Sandoz PentasoneSandoz Canada Incorporated
TaclonexWarner Chilcott (US), LLC
Taclonex ScalpWarner Chilcott (US), LLC
Valisone-G CreamValeant Canada Lp Valeant Canada S.E.C.
Valisone-G OintmentValeant Canada Lp Valeant Canada S.E.C.
Salts
Name/CASStructureProperties
Betamethasone acetate
ThumbNot applicableDBSALT001422
Betamethasone benzoate
ThumbNot applicableDBSALT001122
Betamethasone dipropionate
ThumbNot applicableDBSALT000851
Betamethasone sodium phosphate
ThumbNot applicableDBSALT000850
Betamethasone valerate
ThumbNot applicableDBSALT000849
Categories
UNII9842X06Q6M
CAS number378-44-9
WeightAverage: 392.4611
Monoisotopic: 392.199902243
Chemical FormulaC22H29FO5
InChI KeyInChIKey=UREBDLICKHMUKA-DVTGEIKXSA-N
InChI
InChI=1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15-,16-,17-,19-,20-,21-,22-/m0/s1
IUPAC Name
(1R,2S,10S,11S,13S,14R,15S,17S)-1-fluoro-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,13,15-trimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-dien-5-one
SMILES
[H][C@@]12C[[email protected]](C)[C@](O)(C(=O)CO)[C@@]1(C)C[[email protected]](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassHydroxysteroids
Direct Parent21-hydroxysteroids
Alternative Parents
Substituents
  • 21-hydroxysteroid
  • Progestogin-skeleton
  • Pregnane-skeleton
  • 20-oxosteroid
  • 17-hydroxysteroid
  • 11-hydroxysteroid
  • 11-beta-hydroxysteroid
  • Oxosteroid
  • Halo-steroid
  • 9-halo-steroid
  • 3-oxosteroid
  • 3-oxo-delta-1,4-steroid
  • Delta-1,4-steroid
  • Tertiary alcohol
  • Cyclic alcohol
  • Alpha-hydroxy ketone
  • Cyclic ketone
  • Secondary alcohol
  • Ketone
  • Halohydrin
  • Fluorohydrin
  • Hydrocarbon derivative
  • Primary alcohol
  • Organooxygen compound
  • Organofluoride
  • Organohalogen compound
  • Carbonyl group
  • Alkyl halide
  • Alkyl fluoride
  • Alcohol
  • Aliphatic homopolycyclic compound
Molecular FrameworkAliphatic homopolycyclic compounds
External Descriptors
Pharmacology
IndicationTopical use (cream, lotion and ointment): for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses
Topical use (foam): relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses of the scalp
Systemic use: for the treatment of edocrine disorders, rheumatic disorders, collagen diseases, dermatological diseases, allergic states, ophthalmic diseases, respiratory diseases, hematologic disorders, neoplastic diseases, edematous states, gastrointestinal diseases, tuberculous meningitis and trichinosis.
PharmacodynamicsBetamethasone and its derivatives, betamethasone sodium phosphate and betamethasone acetate, are synthetic glucocorticoids. Used for its antiinflammatory or immunosuppressive properties, betamethasone is combined with a mineralocorticoid to manage adrenal insufficiency and is used in the form of betamethasone benzoate, betamethasone dipropionate, or betamethasone valerate for the treatment of inflammation due to corticosteroid-responsive dermatoses. Betamethasone and clotrimazole are used together to treat cutaneous tinea infections.
Mechanism of actionBetamethasone is a glucocorticoid receptor agonist. This leads to changes in genetic expression once this complex binds to the GRE. The antiinflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. The immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding. Betamethasone binds to plasma transcortin, and it becomes active when it is not bound to transcortin.
Related Articles
AbsorptionMinimal if applied topically.
Volume of distributionNot Available
Protein binding64%
Metabolism

Hepatic

Route of eliminationNot Available
Half life5.6 hours
ClearanceNot Available
ToxicitySymptoms of overdose include burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.992
Blood Brain Barrier+0.9781
Caco-2 permeable+0.8304
P-glycoprotein substrateSubstrate0.7862
P-glycoprotein inhibitor INon-inhibitor0.8112
P-glycoprotein inhibitor IINon-inhibitor0.8134
Renal organic cation transporterNon-inhibitor0.7971
CYP450 2C9 substrateNon-substrate0.8733
CYP450 2D6 substrateNon-substrate0.9115
CYP450 3A4 substrateSubstrate0.7315
CYP450 1A2 substrateNon-inhibitor0.938
CYP450 2C9 inhibitorNon-inhibitor0.9106
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9247
CYP450 3A4 inhibitorNon-inhibitor0.8308
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9169
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.9399
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.1482 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9558
hERG inhibition (predictor II)Inhibitor0.5091
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Schering corp sub schering plough corp
  • Parke davis div warner lambert co
  • Parke davis pharmaceutical research div warner lambert co
  • Altana inc
  • Glenmark generics inc usa
  • Perrigo new york inc
  • Taro pharmaceuticals usa inc
  • Tolmar inc
  • Schering corp
  • Savage laboratories inc div altana inc
  • Actavis mid atlantic llc
  • E fougera div altana inc
  • Pharmaderm div altana inc
  • Teva pharmaceuticals usa inc
  • Alpharma us pharmaceuticals division
  • Taro pharmaceuticals inc
  • Teva pharmaceuticals usa
  • Watson laboratories inc
  • Connectics corp
  • Tj roaco ltd
  • Pharmafair inc
  • Stat trade inc
Packagers
Dosage forms
FormRouteStrength
Geltopical0.025 %
Kitintra-articular; intralesional; intramuscular
Liquidtopical.1 %
Creamtopical.1 %
Lotiontopical1.22 mg
Ointmenttopical1 mg
Geltopical.1 %
Suspensionintra-articular; intralesional; intramuscular
Injection, suspensionepidural; intramuscular; intraspinal; intrathecal
Creamtopical.64 mg/g
Cream, augmentedtopical.5 mg/g
Geltopical.5 mg/g
Geltopical.64 mg/g
Lotiontopical.5 mg/g
Lotion, augmentedtopical.5 mg/mL
Ointmenttopical.05 mg/g
Ointment, augmentedtopical.5 mg/g
Lotiontopical.64 mg/mL
Injection, suspensionintra-articular; intralesional; intramuscular
Injection, solutionepidural; intramuscular; intraspinal; intrathecal12 mg/mL
Creamtopical1 mg/g
Creamtopical1.2 mg/g
Lotioncutaneous1 mg/mL
Lotiontopical1 mg/mL
Ointmenttopical1 mg/g
Ointmenttopical1.2 mg/g
Creamtopical.64 mg
Lotiontopical.64 mg
Ointmenttopical.64 mg
Patchtopical2.25 mg
Dropsophthalmic; otic.1 %
Liquidophthalmic; otic0.1 %
Tablettopical0.1 mg
Enemarectal5 mg
Tabletoral.5 mg
Tablet (effervescent)oral0.5 mg
Ointmenttopical.1 %
Ointmenttopical0.1 %
Tablet (extended-release)oral1 mg
Injection, suspensionintra-articular; intralesional; intramuscular; soft tissue
Injection, suspensionintramuscular
Suspensionintra-articular; intrabursal; intradermal; intramuscular
Tabletoral0.5 mg
Lotiontopical
Lotiontopical.5 mg/mL
Lotiontopical0.5 mg
Ointmenttopical.5 mg/g
Creamtopical.5 mg/g
Creamtopical0.05 %
Liquidophthalmic; otic
Geltopical
Creamtopical.05 g/100g
Ointmenttopical.05 g/100g
Aerosol, foamtopical
Ointmentophthalmic
Creamtopical
Aerosol, foamtopical0.12 %
Aerosol, foamtopical1.2 mg/g
Kitepidural; infiltration; intra-articular; intralesional; intramuscular; topical
Creamtopical0.1 %
Creamtopical0.5 mg
Ointmenttopical0.5 mg
Creamtopical.05 %
Lotiontopical0.05 %
Ointmenttopical0.05 %
Lotiontopical.5 mg
Ointmenttopical.5 mg
Lotiontopical.1 %
Ointmenttopical.05 %
Solutionophthalmic; otic
Spraytopical.5 mg/g
Ointmenttopical
Suspensiontopical
Spray, meteredtopical
Lotiontopical.05 %
Creamtopical.5 mg
Lotiontopical0.1 %
Prices
Unit descriptionCostUnit
Luxiq 0.12% Foam 100 gm Can325.17USD can
Luxiq 0.12% Foam 50 gm Can174.7USD can
Diprolene 0.05% Lotion 60ml Bottle148.19USD bottle
Diprolene 0.05% Ointment 50 gm Tube147.41USD tube
Diprolene AF 0.05% Cream 50 gm Tube147.02USD tube
Betamethasone Dipropionate Aug 0.05% Ointment 45 gm Tube118.42USD tube
Diprolene 0.05% Gel 50 gm Tube103.99USD tube
Betamethasone Dipropionate Aug 0.05% Lotion 60ml Bottle100.64USD bottle
Betamethasone Dipropionate Aug 0.05% Cream 50 gm Tube88.66USD tube
Betamethasone Dipropionate Aug 0.05% Gel 50 gm Tube88.26USD tube
Diprolene 0.05% Lotion 30ml Bottle78.79USD bottle
Betamethasone acetate powd78.03USD g
Diprolene 0.05% Ointment 15 gm Tube69.38USD tube
Diprolene AF 0.05% Cream 15 gm Tube69.38USD tube
Betamethasone Dipropionate Aug 0.05% Ointment 15 gm Tube58.83USD tube
Betamethasone sod phos powder56.61USD g
Diprolene 0.05% Gel 15 gm Tube49.99USD tube
Betamethasone dp powder48.96USD g
Betamethasone valerate powd47.89USD g
Maxivate 0.05% Cream 45 gm Tube44.99USD tube
Betamethasone Dipropionate 0.05% Lotion 60ml Bottle40.4USD bottle
Betamethasone Dipropionate Aug 0.05% Cream 15 gm Tube39.62USD tube
Betamethasone Dipropionate Aug 0.05% Gel 15 gm Tube39.46USD tube
Betamethasone Dipropionate 0.05% Ointment 45 gm Tube19.67USD tube
Betamethasone Dipropionate 0.05% Cream 45 gm Tube18.9USD tube
Betamethasone Valerate 0.1% Lotion 60ml Bottle16.99USD bottle
Betamethasone Valerate 0.1% Ointment 45 gm Tube15.87USD tube
Beta-Val 0.1% Lotion 60ml Bottle14.99USD bottle
Betamethasone Dipropionate 0.05% Ointment 15 gm Tube13.51USD tube
Betamethasone Dipropionate 0.05% Cream 15 gm Tube12.99USD tube
Betamethasone Valerate 0.1% Cream 45 gm Tube12.99USD tube
Beta-Val 0.1% Cream 45 gm Tube12.99USD tube
Betamethasone Valerate 0.1% Cream 15 gm Tube11.99USD tube
Betamethasone Valerate 0.1% Ointment 15 gm Tube11.99USD tube
Beta-Val 0.1% Cream 15 gm Tube11.99USD tube
Betnesol (5 mg/100Ml) 5 mg/enm Enema9.51USD enema
Celestone soluspan 6 mg/ml8.08USD ml
Betamethasone ac-sp 6 mg/ml vial7.68USD ml
Luxiq 0.12% foam5.01USD g
Diprolene af 0.05% cream4.19USD g
Lotrisone 1-0.05% Lotion2.89USD ml
Lotrisone cream2.71USD g
Betamethasone dp aug 0.05% crm2.17USD g
Diprolene Glycol 0.05 % Glycol Cream0.54USD g
Diprolene Glycol 0.05 % Glycol Ointment0.54USD g
Ratio-Topilene 0.05 % Glycol Cream0.54USD g
Ratio-Topilene 0.05 % Glycol Ointment0.54USD g
Diprolene Glycol 0.05 % Glycol Lotion0.49USD g
Ratio-Topilene 0.05 % Glycol Lotion0.49USD g
Prevex B 0.1 % Occlusive Cream0.4USD g
Beta-val 0.1% cream0.32USD g
Ratio-Ectosone Regular 0.1 % Lotion0.3USD g
Ratio-Ectosone Mild 0.05 % Lotion0.23USD g
Diprosone 0.05 % Ointment0.23USD g
Ratio-Topisone 0.05 % Ointment0.23USD g
Diprosone 0.05 % Cream0.21USD g
Diprosone 0.05 % Lotion0.21USD g
Ratio-Topisone 0.05 % Cream0.21USD g
Ratio-Topisone 0.05 % Lotion0.21USD g
Betamethasone va 0.1% cream0.14USD g
Betaderm Regular 0.1 % Ointment0.1USD g
Ratio-Ectosone Regular 0.1 % Cream0.1USD g
Valisone Scalp 0.1 % Lotion0.1USD g
Betaderm Regular 0.1 % Cream0.09USD g
Ratio-Ectosone Scalp 0.1 % Lotion0.09USD g
Betaderm Mild 0.05 % Ointment0.07USD g
Betaderm Mild 0.05 % Cream0.06USD g
Ratio-Ectosone Mild 0.05 % Cream0.06USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6126920 No1996-03-012016-03-01Us
US6753013 No2000-01-272020-01-27Us
US6787529 No2000-01-272020-01-27Us
US7078058 No1997-05-242017-05-24Us
US9119781 No2011-06-102031-06-10Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point232 °CU.S. Patent 3,164,618
water solubility66.5 mg/L (at 25 °C)EPA
logP1.94HANSCH,C ET AL. (1995)
logS-3.77ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.0505 mg/mLALOGPS
logP1.93ALOGPS
logP1.68ChemAxon
logS-3.9ALOGPS
pKa (Strongest Acidic)12.42ChemAxon
pKa (Strongest Basic)-3.3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area94.83 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity102.49 m3·mol-1ChemAxon
Polarizability40.88 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Fernando AHUMADA AYALA, “SKIN-CARE PREPARATIONS CONTAINING MUPIROCIN AND BETAMETHASONE DIPROPIONATE.” U.S. Patent US20100063015, issued March 11, 2010.

US20100063015
General ReferencesNot Available
External Links
ATC CodesA07EA04C05AA05D07AC01D07BC01D07CC01D07XC01H02AB01R01AD06R03BA04S01BA06S01BB04S01CA05S01CB04S02BA07S03BA03S03CA06
AHFS Codes
  • 84:06.00
PDB EntriesNot Available
FDA labelDownload (37.5 KB)
MSDSDownload (71.9 KB)
Interactions
Drug Interactions
Drug
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Betamethasone.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Betamethasone.
AldesleukinBetamethasone may decrease the antineoplastic activities of Aldesleukin.
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Betamethasone.
Amphotericin BBetamethasone may increase the hypokalemic activities of Amphotericin B.
AprepitantThe serum concentration of Betamethasone can be increased when it is combined with Aprepitant.
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Betamethasone.
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Betamethasone.
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Betamethasone.
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Betamethasone.
CapromabBetamethasone may decrease effectiveness of Capromab as a diagnostic agent.
CeritinibBetamethasone may increase the hyperglycemic activities of Ceritinib.
ChlorotrianiseneThe serum concentration of Betamethasone can be increased when it is combined with Chlorotrianisene.
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Betamethasone.
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin can be decreased when used in combination with Betamethasone.
DeferasiroxThe risk or severity of adverse effects can be increased when Betamethasone is combined with Deferasirox.
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Betamethasone.
DesmopressinThe risk or severity of adverse effects can be increased when Betamethasone is combined with Desmopressin.
DigoxinBetamethasone may increase the arrhythmogenic activities of Digoxin.
DihydrotachysterolThe risk or severity of adverse effects can be increased when Dihydrotachysterol is combined with Betamethasone.
DihydrotestosteroneBetamethasone may increase the fluid retaining activities of Dihydrotestosterone.
FosaprepitantThe serum concentration of Betamethasone can be increased when it is combined with Fosaprepitant.
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Betamethasone.
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Betamethasone.
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Betamethasone.
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Betamethasone.
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Betamethasone.
IcosapentThe risk or severity of adverse effects can be increased when Betamethasone is combined with Icosapent.
IndacaterolIndacaterol may increase the hypokalemic activities of Betamethasone.
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Betamethasone.
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Betamethasone.
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Betamethasone.
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Betamethasone.
Insulin HumanThe therapeutic efficacy of Insulin Regular can be decreased when used in combination with Betamethasone.
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Betamethasone.
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Betamethasone.
LeflunomideThe risk or severity of adverse effects can be increased when Betamethasone is combined with Leflunomide.
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Betamethasone.
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Betamethasone.
MifepristoneThe therapeutic efficacy of Betamethasone can be decreased when used in combination with Mifepristone.
MitotaneThe serum concentration of Betamethasone can be decreased when it is combined with Mitotane.
NatalizumabThe risk or severity of adverse effects can be increased when Betamethasone is combined with Natalizumab.
NelfinavirThe serum concentration of Betamethasone can be increased when it is combined with Nelfinavir.
NicorandilThe risk or severity of adverse effects can be increased when Betamethasone is combined with Nicorandil.
OxandroloneBetamethasone may increase the fluid retaining activities of Oxandrolone.
PhenytoinThe serum concentration of Betamethasone can be decreased when it is combined with Phenytoin.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Betamethasone.
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Betamethasone.
RoflumilastRoflumilast may increase the immunosuppressive activities of Betamethasone.
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Betamethasone.
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Betamethasone.
SparfloxacinThe risk or severity of adverse effects can be increased when Betamethasone is combined with Sparfloxacin.
TacrineThe risk or severity of adverse effects can be increased when Betamethasone is combined with Tacrine.
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Betamethasone.
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Betamethasone.
TestosteroneBetamethasone may increase the fluid retaining activities of Testosterone.
TofacitinibBetamethasone may increase the immunosuppressive activities of Tofacitinib.
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Betamethasone.
TorasemideBetamethasone may increase the hypokalemic activities of Torasemide.
TrastuzumabTrastuzumab may increase the neutropenic activities of Betamethasone.
TrichlormethiazideBetamethasone may increase the hypokalemic activities of Trichlormethiazide.
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Betamethasone.
WarfarinBetamethasone may increase the anticoagulant activities of Warfarin.
Food Interactions
  • Take with food to reduce irritation.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Could act as a coactivator for STAT5-dependent transcription upon grow...
Gene Name:
NR3C1
Uniprot ID:
P04150
Molecular Weight:
85658.57 Da
References
  1. Tanigawa K, Nagase H, Ohmori K, Tanaka K, Miyake H, Kiniwa M, Ikizawa K: Species-specific differences in the glucocorticoid receptor transactivation function upon binding with betamethasone-esters. Int Immunopharmacol. 2002 Jun;2(7):941-50. [PubMed:12188035 ]
  2. Aida K, Shi Q, Wang J, VandeBerg JL, McDonald T, Nathanielsz P, Wang XL: The effects of betamethasone (BM) on endothelial nitric oxide synthase (eNOS) expression in adult baboon femoral arterial endothelial cells. J Steroid Biochem Mol Biol. 2004 Aug;91(4-5):219-24. [PubMed:15336699 ]
  3. Johnstone JF, Bocking AD, Unlugedik E, Challis JR: The effects of chorioamnionitis and betamethasone on 11beta hydroxysteroid dehydrogenase types 1 and 2 and the glucocorticoid receptor in preterm human placenta. J Soc Gynecol Investig. 2005 May;12(4):238-45. [PubMed:15866114 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Oxygen binding
Specific Function:
Catalyzes the formation of aromatic C18 estrogens from C19 androgens.
Gene Name:
CYP19A1
Uniprot ID:
P11511
Molecular Weight:
57882.48 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Yates CR, Chang C, Kearbey JD, Yasuda K, Schuetz EG, Miller DD, Dalton JT, Swaan PW: Structural determinants of P-glycoprotein-mediated transport of glucocorticoids. Pharm Res. 2003 Nov;20(11):1794-803. [PubMed:14661924 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on July 27, 2016 01:58